---
input_text: 'Intravitreal reinjection of triamcinolone for exudative age-related macular
  degeneration.OBJECTIVE: To evaluate the outcome of repeated intravitreal injections
  of triamcinolone acetonide for the treatment of exudative age-related macular degeneration.
  METHODS: This prospective, comparative nonrandomized clinical interventional study
  included 13 patients with progressive exudative age-related macular degeneration
  with occult, or predominantly occult, subfoveal neovascularization. All patients
  had shown an increase or stabilization of visual acuity after a first intravitreal
  injection of 25 mg of triamcinolone acetonide. They received a second intravitreal
  injection of 25 mg of triamcinolone acetonide 3.1 to 18 months after the first injection.
  Mean +/- SD follow-up time after the second injection was 5.2 +/- 3.6 months (median,
  5.3 months). A control group included 24 patients with exudative age-related macular
  degeneration who did not receive treatment for their maculopathy. The main outcome
  measures were visual acuity and intraocular pressure. RESULTS: In the study group,
  mean +/- SD visual acuity increased significantly (P =.005 and P =.003, respectively)
  from 0.17 +/- 0.11 to 0.32 +/- 0.26 and from 0.15 +/- 0.14 to 0.23 +/- 0.19, respectively,
  after the first and second injections. An increase in visual acuity was found for
  10 patients (77%) after the first and second injections. In the control group, visual
  acuity did not vary significantly during follow-up (P =.81). The difference in change
  in visual acuity between the study group and control group was significant (P =.01
  [Snellen lines] and P =.05 [logMAR units]). The peak in visual acuity and, in a
  chronologically parallel manner, the peak in intraocular pressure elevation occurred
  2 to 5 months after each injection. CONCLUSIONS: Repeated intravitreal injection
  of 25 mg of triamcinolone acetonide may lead to an increase in visual acuity in
  patients with exudative age-related macular degeneration, with the peak in visual
  acuity and intraocular pressure elevation occurring about 2 to 5 months after each
  injection.'
raw_completion_output: |-
  action: <Intravitreal injection of triamcinolone acetonide>
  disease: <Exudative age-related macular degeneration>
  symptom: <Increase in visual acuity; Intraocular pressure elevation>
  action_to_disease: <Intravitreal injection of triamcinolone acetonide TREATS Exudative age-related macular degeneration>
  action_to_symptom: <Intravitreal injection of triamcinolone acetonide CAUSES Increase in visual acuity;Intravitreal injection of triamcinolone acetonide CAUSES Intraocular pressure elevation>
  triples: <Intravitreal injection of triamcinolone acetonide TREATS Exudative age-related macular degeneration;Intravitreal injection of triamcinolone acetonide CAUSES Increase in visual acuity;Intravitreal injection of triamcinolone acetonide CAUSES Intraocular pressure elevation>
prompt: |+
  From the text below, extract the following entities in the following format:

  subject: <the value for subject>
  predicate: <the value for predicate>
  object: <the value for object>
  qualifier: <A qualifier for the statements, e.g. "NOT" for negation>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Intravitreal injection of triamcinolone acetonide CAUSES Intraocular pressure elevation>

  ===

extracted_object:
  triples:
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: TREATS
      object: Exudative age-related macular degeneration
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: CAUSES
      object: Increase in visual acuity
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: CAUSES
      object: Intraocular pressure elevation
  action:
    - <Intravitreal injection of triamcinolone acetonide>
  disease:
    - <Exudative age-related macular degeneration>
  symptom:
    - <Increase in visual acuity
    - Intraocular pressure elevation>
  action_to_disease:
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: TREATS
      object:
        - Exudative age-related macular degeneration
  action_to_symptom:
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: CAUSES
      object:
        - Increase in visual acuity
    - subject: Intravitreal injection of triamcinolone acetonide
      predicate: CAUSES
      object:
        - Intraocular pressure elevation
named_entities:
  - id: MONDO:0005365
    label: hearing loss
  - id: MONDO:0008891
    label: Brown-Vialetto-Van Laere syndrome
  - id: MONDO:0003608
    label: optic atrophy
  - id: MONDO:0100062
    label: infantile spasms
  - id: MONDO:0005027
    label: seizures
  - id: MONDO:0005047
    label: infertility
  - id: MAXO:0010030
    label: bone marrow transplantation
  - id: MONDO:0009974
    label: familial hemophagocytic lymphohistiocytosis
  - id: MONDO:0011382
    label: sickle cell disease
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: MONDO:0000440
    label: Metabolic acidosis
  - id: MONDO:0009666
    label: Holocarboxylase synthetase deficiency
  - id: MONDO:0015454
    label: Multiple carboxylase deficiency
  - id: MONDO:0001531
    label: Coagulopathy
  - id: MONDO:0020300
    label: Autosomal dominant nocturnal frontal lobe epilepsy
  - id: MONDO:0000903
    label: myoclonus-dystonia
  - id: MAXO:0000943
    label: Deep brain stimulation
  - id: HP:0001252
    label: Hypotonia
  - id: MAXO:0001082
    label: Trabeculectomy
  - id: MONDO:0005129
    label: Cataract
  - id: HP:0000253
    label: Progressive microcephaly
  - id: HP:0001263
    label: Global developmental delay
  - id: MONDO:0004183
    label: axonal neuropathy
  - id: HP:0011096
    label: demyelination
  - id: MONDO:0008961
    label: autosomal recessive demyelinating Charcot-Marie-Tooth disease type 4A
  - id: MONDO:0007947
    label: Marfan's syndrome
  - id: MONDO:0004691
    label: <Autosomal dominant polycystic kidney disease (ADPKD)
  - id: MONDO:0005015
    label: Diabetes mellitus
  - id: MONDO:0004522
    label: Peritonitis
  - id: MAXO:0000603
    label: Peritoneal Dialysis
  - id: MONDO:0003441
    label: dystonia
  - id: MONDO:0001341
    label: IgA deficiency
  - id: MONDO:0009693
    label: multiple myeloma
  - id: MONDO:0011787
    label: Limb-girdle muscular dystrophy type 2I (LGMD2I)
  - id: MONDO:0009662
    label: <MPS VII (Sly disease)
  - id: MONDO:0020546
    label: acute GVHD
  - id: MONDO:0005155
    label: Liver cirrhosis
  - id: MONDO:0002771
    label: Pulmonary fibrosis
  - id: MONDO:0004992
    label: Cancer
  - id: HP:0003394
    label: Muscle cramps
  - id: MONDO:0015286
    label: <Complete DiGeorge syndrome (cDGS)
  - id: MONDO:0019098
    label: Autoimmune thrombocytopenia
  - id: MONDO:0004126
    label: Thyroiditis
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0010042
    label: Thymus transplantation
  - id: MONDO:0010421
    label: X-linked Agammaglobulinemia
  - id: MONDO:0007765
    label: Hyperostosis cranialis interna
  - id: MAXO:0000780
    label: growth hormone therapy
  - id: MONDO:0018997
    label: Noonan syndrome
  - id: HP:0004322
    label: short stature
  - id: MONDO:0015168
    label: Arthrogryposis multiplex congenita
  - id: MONDO:0018940
    label: Congenital myasthenic syndromes
  - id: MAXO:0001077
    label: splenectomy
  - id: MONDO:0010518
    label: Wiskott-Aldrich syndrome
  - id: MONDO:0011724
    label: Glut-1 deficiency syndrome
  - id: HP:0005484
    label: acquired microcephaly
  - id: HP:0001257
    label: spasticity
  - id: HP:0001251
    label: ataxia
  - id: HP:0011972
    label: hypoglycorrhachia
  - id: MAXO:0000098
    label: Fasting
  - id: MONDO:0019169
    label: Pyruvate dehydrogenase complex deficiency
  - id: MONDO:0000188
    label: GLUT1 deficiency syndrome
  - id: HP:0001250
    label: Seizures
  - id: HP:0001946
    label: Ketosis
  - id: MONDO:0019353
    label: Stargardt disease
  - id: MONDO:0015974
    label: Severe Combined Immune Deficiency (SCID)
  - id: MONDO:0004980
    label: eczema
  - id: MONDO:0007179
    label: autoimmunity
  - id: HP:0001892
    label: hemorrhagic diathesis
  - id: HP:0000964
    label: eczema
  - id: HP:0002960
    label: autoimmunity
  - id: MONDO:0009561
    label: alpha-mannosidosis
  - id: MAXO:0000011
    label: physical therapy
  - id: MAXO:0010203
    label: echocardiography
  - id: MONDO:0005380
    label: avascular necrosis
  - id: MONDO:0005149
    label: pulmonary hypertension
  - id: MONDO:0005632
    label: acute chest syndrome
  - id: MAXO:0000652
    label: angiotensin-converting enzyme inhibitor therapy
  - id: MONDO:0800385
    label: iron overload
  - id: MAXO:0035078
    label: pulmonary function testing
  - id: MONDO:0009061
    label: cystic fibrosis
  - id: MONDO:0010926
    label: familial hypocalciuric hypercalcemia type 3 (FHH3)
  - id: MONDO:0001566
    label: hypercalcemia
  - id: HP:0001508
    label: poor weight gain
  - id: MAXO:0035059
    label: Nerve conduction studies
  - id: MAXO:0010033
    label: Umbilical cord blood transplantation
  - id: MONDO:0018868
    label: metachromatic leukodystrophy
